A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Phase 1
150
about 2.5 years
18+
5 sites in AZ, MI, NC +2
About this study
This trial is testing a new treatment called SON-DP in people with advanced or metastatic solid tumors that have returned after other treatments. The goal is to see if this treatment is safe and how it works in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take SON-DP
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II), Number of participants with AEs, with abnormal vital signs, abnormal ECG readings, abnormal clinical laboratory tests results, abnormal physical examinations and abnormal ECOG performance status.
Secondary: Cmax, DCR, DOR, ORR, OS, PFS, T1/2, TTP
Oncology